Orally active leukemia inhibitory factor (lif) antagonists for the treatment of cancer
US-2024124515-A1 · Apr 18, 2024 · US
Progesterone receptor antagonists
US9109004B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9109004-B2 |
| Application number | US-201113578500-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 8, 2011 |
| Priority date | Feb 10, 2010 |
| Publication date | Aug 18, 2015 |
| Grant date | Aug 18, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of formula I with progesterone-antagonizing action and methods of production thereof, use thereof for the treatment and/or prevention of diseases and use thereof for producing medicinal products for the treatment and/or prevention of diseases, in particular uterine fibroids (myomata, uterine leiomyomata), endometriosis, heavy menstrual bleeding, meningiomata, hormone-dependent breast cancers and menopause-associated complaints or for fertility control and emergency contraception.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of formula I in which R 1 stands either for a residue Y or for a phenyl ring substituted with Y, Y stands for a group R 2 and R 3 are identical or different and stand for hydrogen, an optionally —N(CH 3 ) 2 ,…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
- C07J43/003Primary
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9109004B2 cover?
- The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of formula I with progesterone-antagonizing action and methods of production thereof, use thereof for the treatment and/or prevention of diseases and use thereof for producing medicinal products for the treatment and/or prevention of diseases, in particular uterine fibroids (myomata, uterine leiomyoma…
- Who is the assignee on this patent?
- Schwede Wolfgang, Klar Ulrich, Möller Carsten, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification C07J43/003. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 18 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).